Angiotensin receptors, autoimmunity, and preeclampsia

Journal of Immunology

Volumn 179, Issue 6, 2007, Pages 3391-3395

  Xia, Yang ^a   Cissy, Chenyi Zhou ^a   Ramin, Susan M ^a   Kellems, Rodney E ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; AUTOANTIBODY;

AUTOIMMUNITY; CLINICAL FEATURE; FETUS CIRCULATION; HIGH RISK PREGNANCY; HUMAN; IMMUNOPATHOGENESIS; KIDNEY ALLOGRAFT REJECTION; MALIGNANT HYPERTENSION; MATERNAL DISEASE; NONHUMAN; PLACENTA DISORDER; PREECLAMPSIA; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY; ANIMAL; AUTOIMMUNE DISEASE; FEMALE; IMMUNOLOGY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; REVIEW;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; RECEPTOR, ANGIOTENSIN, TYPE 1;

EID: 35748966703     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.6.3391     Document Type: Short Survey

References (48)

1. Redman, C. W., and I. L. Sargent. 2005. Latest advances in understanding preeclampsia. Science 308: 1592-1594.
2. Roberts, J. M. 2000. Preeclampsia: what we know and what we do not know. Semin. Perinatol. 24: 24-28.
3. Granger, J. P., B. T. Alexander, M. T. Llinas, W. A. Bennett, and R. A. Khalil. 2001. Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hypertension 38: 718-722.
4. Gleicher, N. 2007. Why much of the pathophysiology of preeclampsia-eclampsia must be of an autoimmune nature. Am. J. Obstet. Gynecol. 196: 5.e1-7.
5. Sargent, I. L., A. M. Borzychowski, and C. W. Redman. 2006. Immunoregulation in normal pregnancy and pre-eclampsia: an overview. Reprod. Biomed. Online 13: 680-686.
6. Wallukat, G., V. Homuth, T. Fischer, C. Lindschau, B. Horstkamp, A. Jupner, E. Baur, E. Nissen, K. Vetter, D. Neichel, et al. 1999. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J. Clin. Invest. 103: 945-952.
7. Xia, Y., H. Y. Wen, S. Bobst, M. C. Day, and R. E. Kellems. 2003. Maternal autoantibodies from preeclampsia patients activate angiotensin receptors on human trophoblast cells. J. Soc. Gyenocol. Investig. 10: 82-93.
8. Xia, Y., H. Y. Wen, and R. E. Kellems. 2002. Angiotensin II inhibits human trophoblast invasiveness through AT-1 receptor activation. J. Biol. Chem. 277: 24601-24608.
9. Bobst, S. M., M. C. Day, L. C. Gilstrap III, Y. Xia, and R. E. Kellems. 2005. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion. Am. J. Hypertens. 18: 330-336.
10. Dechend, R., V. Homuth, G. Wallukat, J. Kreuzer, J. K. Park, J. Theuer, A. Juepner, D. C. Gulba, N. Mackman, H. Haller, and F. C. Luft. 2000. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation 101: 2382-2387.
11. Dechend, R., C. Viedt, D. N. Muller, B. Ugele, R. P. Brandes, G. Wallukat, J. K. Park, J. Janke, P. Barta, J. Theuer, et al. 2003. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation 107: 1632-1639.
12. Chaiworapongsa, T., R. Romero, J. Espinoza, E. Bujold, Y. Mee Kim, L. F. Goncalves, R. Gomez, and S. Edwin. 2004. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am. J. Obstet. Gynecol. 190: 1541-1547; discussion 1547-1550.
13. Levine, R. J., S. E. Maynard, C. Qian, K. H. Lim, L. J. England, K. F. Yu, E. F. Schisterman, R. Thadhani, B. P. Sachs, F. H. Epstein, et al. 2004. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350: 672-683.
14. Zhou, C. C., S. Ahmad, T. Mi, L. Xia, S. Abbasi, P. W. Hewett, C. X. Sun, A. Ahmed, R. E. Kellems, and Y. Xia. 2007. Angiotensin II induces soluble fms-like tyrosine kinase-1 (sFlt-1) release via calcineurin signaling pathway in pregnancy. Circ. Res. 100: 88-95.
15. Chaiworapongsa, T., R. Romero, Y. M. Kim, G. J. Kim, M. R. Kim, J. Espinoza, E. Bujold, L. Goncalves, R. Gomez, S. Edwin, and M. Mazor. 2005. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J. Matern. Fetal Neonatal Med. 17: 3-18.
16. Koga, K., Y. Osuga, O. Yoshino, Y. Hirota, X. Ruimeng, T. Hirata, S. Takeda, T. Yano, O. Tsutsumi, and Y. Taketani. 2003. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J. Clin. Endocrinol. Metab. 88: 2348-2351.
17. Nagamatsu, T., T. Fujii, M. Kusumi, L. Zou, T. Yamashita, Y. Osuga, M. Momoeda, S. Kozuma, and Y. Taketani. 2004. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 145: 4838-4845.
18. Tsatsaris, V., F. Goffin, C. Munaut, J.-F. Brichant, M.-R. Pignon, A. Noel, J.-P. Schaaps, D. Cabrol, F. Frankenne, and J.-M. Foidart. 2003. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J. Clin. Endocrinol. Metab. 88: 5555-5563.
19. Maynard, S. E., J. Y. Min, J. Merchan, K. H. Lim, J. Li, S. Mondal, T. A. Libermann, J. P. Morgan, F. W. Sellke, I. E. Stillman, et al. 2003. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111: 649-658.
20. Herse, F., R. Dechend, N. K. Harsem, G. Wallukat, J. Janke, F. Qadri, L. Hering, D. N. Muller, F. C. Luft, and A. C. Staff. 2007. Dysregulation of the circulating and tissue-based renin-angiotensin system in preeclampsia. Hypertension 49: 604-611.
21. Walther, T., G. Wallukat, A. Jank, S. Bartel, H. P. Schultheiss, R. Faber, and H. Stepan. 2005. Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension 46: 1275-1279.
22. Zhou, C. C., A. Ahmad, L. Xia, M. C. Day, S. Ramin, R. E. Kellems, and Y. Xia. 2006. Upregulation of placental soluble fms-like tyrosine kinase 1 (sFlt-) by AT1-receptor agonistic autoantibodies in preeclampsia. Hypertens. Pregnancy 25: 38.
23. Bai, M. 2004. Dimerization of G-protein-coupled receptors: roles in signal transduction. Cell. Signal. 16: 175-186.
24. Breitwieser, G. E. 2004. G protein-coupled receptor oligomerization: implications for G protein activation and cell signaling. Circ. Res. 94: 17-27.
25. Terrillon, S., and M. Bouvier. 2004. Roles of G-protein-coupled receptor dimerization. EMBO Rep. 5: 30-34.
26. AbdAlla, S., H. Lother, A. el Massiery, and U. Quitterer. 2001. Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness (see comment). Nat. Med. 7: 1003-1009.
27. AbdAlla, S., H. Lother, A. Langer, Y. el Faramawy, and U. Quitterer. 2004. Factor XIIIA transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of atherosclerosis. Cell 119: 343-354.
28. AbdAlla, S., H. Lother, and U. Quitterer. 2000. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 407: 94-98.
29. Pearce, S. H., and T. R. Merriman. 2006. Genetic progress towards the molecular basis of autoimmunity. Trends Mol. Med. 12: 90-98.
30. Fujinami, R. S., M. G. von Herrath, U. Christen, and J. L. Whitton. 2006. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin. Microbiol. Rev. 19: 80-94.
31. Barak, Y. 2006. The immune system and happiness. Autoimmun. Rev. 5: 523-527.
32. Roberts, J. M., and K. Y. Lain. 2002. Recent insights into the pathogenesis of preeclampsia. Placenta 23: 359-372.
33. Gadonski, G., B. B. LaMarca, E. Sullivan, W. Bennett, D. Chandler, and J. P. Granger. 2006. Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of interleukin 6. Hypertension 48: 711-716.
34. Dechend, R., M. Llinas, S. Caluwaerts, F. Herse, B. Lamarca, D. N. Mueller, F. C. Luft, R. Pijnenborg, G. Wallukat, and J. P. Granger. 2006. Agonistic autoantibodies to the AT1 receptor in rat models of preeclampsia: induced by chronic reduction in uterine perfusion pressure (RUPP) and low dose TNF-α infusion. Hypertens. Pregnancy 25: 70 (Abstr.).
35. Roberts, L., B. B. LaMarca, L. Fournier, J. Bain, K. Cockrell, and J. P. Granger. 2006. Enhanced endothelin synthesis by endothelial cells exposed to sera from pregnant rats with decreased uterine perfusion. Hypertension 47: 615-618.
36. LaMarca, B. B., W. A. Bennett, B. T. Alexander, K. Cockrell, and J. P. Granger. 2005. Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis factor-α. Hypertension 46: 1022-1025.
37. Llinas M., G. Wallukat, R. Dechend, D. N. Mueller, F. C. Luft, B, T. Alexander, B. B. Lamarca, and J. P. Granger. 2005. Agonistic autoantibodies to the AT1 receptor in a rat model of preeclampsia induced by chronic reductions in uterine perfusion pressure (RUPP). Hypertension 46: 883 (Abstr).
38. Fu, M. L., H. Herlitz, W. Schulze, G. Wallukat, P. Micke, P. Eftekhari, K. G. Sjogren, A. Hjalmarson, W. Muller-Esterl, and J. Hoebeke. 2000. Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J. Hypertens. 18: 945-953.
39. Liao, Y. H., Y. M. Wei, M. Wang, Z. H. Wang, H. T. Yuan, and L. X. Cheng. 2002. Autoantibodies against AT1-receptor and α1-adrenergic receptor in patients with hypertension. Hypertens. Res. 25: 641-646.
40. Dragun, D., D. N. Muller, J. H. Brasen, L. Fritsche, M. Nieminen-Kelha, R. Dechend, U. Kintscher, B. Rudolph, J. Hoebeke, D. Eckert, et al. 2005. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection (see comment). N. Engl. J. Med. 352: 558-569.
41. Chistiakov, D. A. 2003. Thyroid-stimulating hormone receptor and its role in Graves' disease. Mol. Genet. Metab. 80: 377-388.
42. Dozio, N., E. Sarugeri, M. Scavini, A. Beretta, C. Belloni, F. Dosio, A. Savi, F. Fazio, F. Sodoyez-Goffaux, and G. Pozza. 2001. Insulin receptor antibodies inhibit insulin uptake by the liver: in vivo 123I-insulin scintigraphic scanning and in vitro characterization in autoimmune hypoglycemia. J. Investig. Med. 49: 85-92.
43. 1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops.[Published erratum appears in 1995 J. Mol. Cell. Cardiol. 27: 2529.]. J. Mol. Cell. Cardiol. 27: 397-406.
44. 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy (see comment). J. Clin. Invest. 113: 1419-1429.
45. Jahns, R., V. Boivin, and M. J. Lohse. 2006. β1-Adrenergic receptor-directed autoimmunity as a cause of dilated cardiomyopathy in rats. Int. J. Cardiol. 112: 7-14.
46. 1- adrenergic receptors in patients with malignant hypertension. Lancet 344: 1660-1663.
47. 1- Adrenergic receptor antibodies in patients with primary hypertension. Hypertension 29: 678-682.
48. Wallukat, G., H. M. Fu, S. Matsui, A. Hjalmarson, and M. L. Fu. 1999. Autoantibodies against M2 muscarinic receptors in patients with cardiomyopathy display non-desensitized agonist-like effects. Life Sci. 64: 465-469.